Wahl Bryan 4

What Happened

• Bryan Wahl, General Counsel of Tarsus Pharmaceuticals (TARS), had 24,236 shares issued to him on March 15, 2026 pursuant to settlement of vested Restricted Stock Units (RSUs).
• On the same date those 24,236 shares were recorded as disposed in four tranches (4,790; 7,248; 7,176; 5,022) at $0.00 per share (derivative dispositions), which equals the full amount issued. The Form 4 shows no cash proceeds from these disposals.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
• Acquired: 24,236 shares via RSU settlement (footnote F1). Disposed: 4,790; 7,248; 7,176; 5,022 shares at $0.00 each (total disposed = 24,236).
• Price/Value: Acquisition reported as RSU settlement (no cash price); disposals reported at $0.00 — no sale proceeds shown on the filing.
• Shares owned after transaction: Not specified in the details provided.
• Notable footnotes: F1 confirms issuance from vested RSUs; F3 clarifies each RSU converts to one share; F4–F7 list grant dates (Mar 2022–Mar 2025) and standard 25% annual vesting schedules. F2 notes 451 shares from the ESPP (June 30, 2025) are included in holdings data.
• Filing timeliness: Filed two days after the transaction date (timely under Form 4 rules).

Context

• These entries reflect a routine equity compensation settlement (RSU vesting) and subsequent surrender/disposition of the same shares (commonly used to cover withholding obligations), not an open-market purchase or sale for investment purposes.
• For retail investors: such compensation settlements are routine and do not necessarily signal insider buying or selling intent. Purchases (open-market buys) typically carry clearer informational value about an insider’s market view.